Search

Displaying results 6561 - 6570 of 10000 in total
  1. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.

  2. Drug

    Depatuxizumab mafodotin

    go.drugbank.com/drugs/DB11731
    Investigational

    Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.

  3. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  4. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

    Synonyms: Anti-CD19 humanized monoclonal antibody conjugated to DM4
  5. Drug

    Englumafusp alfa

    go.drugbank.com/drugs/DB19341
    Investigational

    Englumafusp alfa is under investigation in clinical trial NCT04077723 (A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab

    Synonyms: humanized immunoglobulin G1-kappa anti-(human B-lymphocyte antigen CD19) modified heterodimer where the heavy and light chain variable regions of one arm have been substituted by three subunits of human
  6. Drug

    Platelet Lysate

    go.drugbank.com/drugs/DB15869
    Investigational

    Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. … [A220188] It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses.

  7. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  8. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  9. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).

    Categories: Bradykinin Receptor Antagonists
  10. Drug

    Mycobacterium w. Vaccine

    go.drugbank.com/drugs/DB15798
    Investigational

    As an immunotherapy, M.w is used against leprosy; the compound also shares antigens with M. tuberculosis. … The Mycobacterium w (M.w) vaccine is a heat-killed suspension derived from a non-pathogenic mycobacterium: mycobacterium indicus pranii.